Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab combined with bevacizumab in people with advanced hepatocellular carcinoma HCC who cannot undergo curative or locoregional therapy. This Phase III, randomized, open-label, sponsor-blinded study includes a safety lead-in period before the main randomized treatment phase to assess tolerability. The study has three groups one receiving tremelimumab, rilvegostomig, and bevacizumab another receiving rilvegostomig and bevacizumab and a third group receiving atezolizumab and bevacizumab. All treatments are given by intravenous infusion. The initial safety lead-in is a single-arm phase focusing on the combination of rilvegostomig, bevacizumab, and tremelimumab, followed by a randomized period comparing the three treatment arms. Participants will be monitored for up to approximately six years to assess overall survival and other measures of treatment effect and safety. Assessments include evaluations of liver cancer progression, immune response, and any adverse events. The study involves regular clinical visits and evaluations to monitor health and treatment effects throughout the study duration.